The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together

On July 4^th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others. The event was attended by Fang Zou, the Executive Vice President of the Shanghai Overseas Returned Scholars Association, along with officials from the Liaison Department and cadres from the United Front Work Department of the Pudong New Area District Committee.

The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together.webp

At the beginning of the event, the Dutch PhD delegation eagerly visited Medicilon's laboratory, where they closely observed the advanced equipment and innovative technologies in the field of new drug development. They witnessed the efficient operation of state-of-the-art instruments and the meticulous and scientific approach of the research project teams in their daily work. This immersive experience conveyed the vitality and boundless promise inherent in biopharmaceutical technological innovation.

At the symposium, Dr. Chunlin Chen warmly welcomed the Dutch PhD delegation and briefly introduced Medicilon's development history and its achievements in empowerment. Medicilon has always focused on the field of preclinical research and development. Medicilon has successfully built cutting-edge technology service platforms, including ADC, PROTAC, CGT, small nucleic acids, and antibodies, empowering 480 IND approvals for clinical trials. Additionally, as a co-founder, the first president, and current honorary president of the Biopharmaceutical Branch of the Shanghai Overseas Returned Scholars Association, as well as a returnee entrepreneur, Dr. Chunlin Chen shared his entrepreneurial insights. Dr. Chen extended a sincere invitation to the Dutch PhD attendees, expressing his hope that they would work together to promote the high-quality development of the biopharmaceutical industry.

Subsequently, all parties engaged in a lively and in-depth discussion on the future trends of the biopharmaceutical industry, new models of international collaboration, and hot topics in innovation and entrepreneurship. The participants expressed their commitment to further strengthening communication and collaboration mechanisms, promoting the aggregation and development of various international innovative elements in the Pudong New Area.

The visit of the Dutch PhD delegation to Medicilon not only provided a valuable platform for mutual exchange but also deeply impressed the Dutch scholars with the open, inclusive, collaborative, and innovative entrepreneurial environment in the Pudong New Area. Looking forward to the near future when these Dutch PhDs return to China after their studies, injecting new vitality into the development of biopharmaceutical entrepreneurship and innovation in Pudong.

Looking ahead, Medicilon will steadfastly uphold the spirit of innovation-driven development and open collaboration. Medicilon will actively broaden its international collaboration horizon, deepen strategic partnerships and technical sharing with top talents and institutions both domestically and internationally. By continuously enhancing its research capabilities, establishing and refining its technology service platforms, Medicilon aims to become a globally trusted comprehensive preclinical research and development service CRO. Medicilon strives to provide robust support for the preclinical development of numerous new and effective drugs.

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

What is Toxicokinetics?

Toxicokinetics is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms toxicokinetics , pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...

阅读全文

Shanghai Medicilon Inc.

搜索此博客